Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 11/20 | 0.49 |
| ▸ | EHMT1 | Q9H9B1 | 8/20 | 0.49 |
| ▸ | SPIN1 | Q9Y657 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21667955 | 0.89 | EHMT2 (0.43) | EHMT2EHMT1SPIN1ALDH1A1KDM4E | |
| SCHEMBL17106567 | 0.88 | EHMT2 (0.54) | EHMT2EHMT1SPIN1ALDH1A1KDM4E | |
| SCHEMBL17106565 | 0.88 | EHMT2 (0.54) | EHMT2EHMT1SPIN1ALDH1A1KDM4E | |
| SCHEMBL17106556 | 0.87 | MAPT (0.36) | ALDH1A1KDM4EMEN1LMNAKMT2A | |
| SCHEMBL17106558 | 0.81 | ALDH1A1 (0.42) | ALDH1A1KDM4EMEN1LMNAKMT2A | |
| SCHEMBL17106580 | 0.78 | KMT2A (0.47) | ALDH1A1MEN1KMT2A | |
| SCHEMBL17106553 | 0.78 | ALDH1A1 (0.47) | EHMT2EHMT1SPIN1ALDH1A1KDM4E | |
| SCHEMBL20303961 | 0.78 | ALDH1A1 (0.53) | EHMT2EHMT1SPIN1ALDH1A1KDM4E | |
| SCHEMBL20028146 | 0.78 | EHMT2 (0.55) | EHMT2EHMT1SPIN1ALDH1A1KDM4E | |
| SCHEMBL7838137 | 0.77 | KDM4E (0.61) | EHMT2EHMT1ALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9284272-B2 | Inhibitors of histone methyltransferase G9a | ABBVIE INC. (US) | 2016-03-15 | — | — | US | disclosed |
| US-20150274660-A1 | INHIBITORS OF HISTONE METHYLTRANSFERASE G9a | ABBVIE INC. | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274660-A1 | INHIBITORS OF HISTONE METHYLTRANSFERASE G9a | EHMT1, EHMT2, EZH2 | EHMT2 2/4885EHMT1 1/4885SPIN1 1994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.